0.00Open0.08Pre Close0 Volume56 Open Interest5.00Strike Price0.00Turnover238.21%IV119.91%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier21DDays to Expiry0.08Extrinsic Value100Contract SizeAmericanOptions Type0.1472Delta0.1731Gamma28.88Leverage Ratio-0.0072Theta0.0002Rho4.25Eff Leverage0.0013Vega
ADC Therapeutics Stock Discussion
ADC Therapeutics Announces Investigator-Initiated Study Abstracts Accepted for Presentation at the 66th ASH Annual Meeting
ADC Therapeutics (NYSE: ADCT) announced two investigator-initiated study abstracts on ZYNLONTA accepted for presentation at the 66th ASH Annual Meeting. The Phase 2 study combining ZYNLONTA with rituximab in relapsed/refractory follicular lymphomashowed a 97.1% overall response rate among 35 patients, with an 80% best complete metabolic respon...
NEWS
ADC Therapeutics Announces $105 Million Underwritten Offering of Common Shares and Pre-Funded Warrants
No comment yet